P915 Prediction of Recurrence After Liver Transplantation for Hcc: Validation of the Afp Model in an Italian Cohort

Risk Factors of Hepatocellular Carcinoma Recurrence After Liver Transplantation: Accuracy of the Alpha-Fetoprotein Model in a Single-Center Experience

“…So far, some extended criteria beyond Milan have demonstrated its validity [5,6,8]. In this respect, the AFP model can be easily applied and has shown promising results in France [9] and Italy [15]. Even using retrospective analysis and a limited series in our study, the AFP model was more useful as a recurrence predictor (and even mortality) than the established BCLC staging, Milan criteria, and up-to-7 criteria.…”

Liver transplantation for hepatocellular carcinoma: evaluation of the alpha‐fetoprotein model in a multicenter cohort from Latin America

“…Efforts to modify LT selection criteria to optimize outcomes in patients with HCC should be considered, not only for the benefit of patients with HCC but also for justice and equipoise to prevail in allocation policies for non‐HCC patients . When the AFP model was assessed in French and Italian cohorts, it proved to be superior to MC. In this study, a minority of patients falling within standard selection criteria exceeded the new AFP model.…”

Utility‐based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha‐fetoprotein model as a survival predictor

“…The AFP model was developed with a robust statistical methodology (with training and internal validation cohorts) in France, and a value >2 is currently adopted in France 19 and the United Kingdom 20 as a criterion for including HCC patients on the waiting list for LT; it recently underwent external validation in Spain 21 and Italy too. 22 A recent US study also indirectly confirmed some important characteristics of the AFP model, particularly showing the strong prognostic power of the AFP 1000 ng/mL threshold in HCC patients undergoing LT. 23 It is important to emphasize, however, that a potential limitation of using the AFP model relates to the non-LT population. It is unclear whether this model would work equally well in patients who do not typically receive a transplant, such as patients with advanced intrahepatic tumor burden (multifocal HCC but <50% involvement) who are usually treated with locoregional therapies alone, and/or those without portal hypertension who would undergo HR.…”

“…The advantage of the AFP model over the Metroticket model is that it is based on preoperative variables. The AFP model was developed with a robust statistical methodology (with training and internal validation cohorts) in France, and a value >2 is currently adopted in France and the United Kingdom as a criterion for including HCC patients on the waiting list for LT; it recently underwent external validation in Spain and Italy too . A recent US study also indirectly confirmed some important characteristics of the AFP model, particularly showing the strong prognostic power of the AFP 1000 ng/mL threshold in HCC patients undergoing LT .…”